Inventor · disambiguated record
Cameron Durrant
Also filed as: DURRANT CAMERON
8 granted patents·16 pending applications·12 citations·filing 2018–2024
81Inventor score
Files withHUMANIGEN INC19ANAVEX LIFE SCIENCES CORP2TARAN THERAPEUTICS INC2MAYO FOUND MEDICAL EDUCATION & RES1
Top patents by PatentIndex Score
24 records- 0190US10813907B2A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapyANAVEX LIFE SCIENCES CORP·Filed 2019·Granted Oct 27, 2020·4 cites·3 claims
- 0286US10870703B2Methods of treating immunotherapy-related toxicity using a GM-CSF antagonistHUMANIGEN INC·Filed 2018·Granted Dec 22, 2020·3 cites·82 claims
- 0383US10927168B2Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumabHUMANIGEN INC·Filed 2019·Granted Feb 23, 2021·2 cites·37 claims
- 0483US10899831B2Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicityHUMANIGEN INC·Filed 2018·Granted Jan 26, 2021·2 cites·14 claims
- 0577US11673962B2Method of increasing the efficacy of CAR-T immunotherapy using lenzilumabHUMANIGEN INC·Filed 2018·Granted Jun 13, 2023·1 cites·16 claims
- 0673US2025171547A1Epha3 directed car-t cells for treatment of tumorsMAYO FOUND MEDICAL EDUCATION & RES·Filed 2024·Application pending·0 cites
- 0771US11690821B2A19-144, A2-73 and certain anticholinesterase inhibitor compositions and method for anti-seizure therapyANAVEX LIFE SCIENCES CORP·Filed 2020·Granted Jul 4, 2023·0 cites·20 claims
- 0865US2025154243A1Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutationsTARAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0963US2024309079A1Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutationsTARAN THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1062US12139544B2EphA3 directed CAR-T cells for treatment of tumorsHUMANIGEN INC·Filed 2020·Granted Nov 12, 2024·0 cites·21 claims
- 1162US2021130488A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2020·Application pending·0 cites
- 1258US2021230262A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1358US2022025034A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1458US2021269518A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1558US2021284714A1Materials and methods for treating cancerHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 1655US11130805B2Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonistHUMANIGEN INC·Filed 2019·Granted Sep 28, 2021·0 cites·32 claims
- 1755US2024317846A1Methods for treating coronavirus infection and resulting inflammation-induced lung injuryHUMANIGEN INC·Filed 2022·Application pending·0 cites
- 1854US2022040229A1Materials and methods for treating cancerHUMANIGEN INC·Filed 2019·Application pending·0 cites
- 1954US2024158467A1Materials and methods for treating cancerHUMANIGEN INC·Filed 2022·Application pending·0 cites
- 2051US2023109208A1Methods for treating coronavirus infection and resulting inflammation-induced lung injuryHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 2151US2022363746A1Methods for treating coronavirus infection and resulting inflammation-induced lung injuryHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 2251US2021322547A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 2351US2021309733A1Methods for treating coronavirus infection and resulting inflammation-induced lung injuryHUMANIGEN INC·Filed 2021·Application pending·0 cites
- 2449US2021290677A1Methods of treating immunotherapy-related toxicity using a gm-csf antagonistHUMANIGEN INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Cameron Durrant files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →